Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

266 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Use of once-weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE Canada multicentre, prospective, observational study.
Yale JF, Catarig AM, Grau K, Harris S, Klimek-Abercrombie A, Rabasa-Lhoret R, Reardon L, Woo V, Liutkus J. Yale JF, et al. Among authors: woo v. Diabetes Obes Metab. 2021 Oct;23(10):2269-2278. doi: 10.1111/dom.14468. Epub 2021 Aug 15. Diabetes Obes Metab. 2021. PMID: 34142429 Free PMC article.
Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
DREAM Trial Investigators; Dagenais GR, Gerstein HC, Holman R, Budaj A, Escalante A, Hedner T, Keltai M, Lonn E, McFarlane S, McQueen M, Teo K, Sheridan P, Bosch J, Pogue J, Yusuf S. DREAM Trial Investigators, et al. Diabetes Care. 2008 May;31(5):1007-14. doi: 10.2337/dc07-1868. Epub 2008 Feb 11. Diabetes Care. 2008. PMID: 18268075 Free article. Clinical Trial.
Type 2 diabetes mellitus management in Canada: is it improving?
Leiter LA, Berard L, Bowering CK, Cheng AY, Dawson KG, Ekoé JM, Fournier C, Goldin L, Harris SB, Lin P, Ransom T, Tan M, Teoh H, Tsuyuki RT, Whitham D, Woo V, Yale JF, Langer A. Leiter LA, et al. Among authors: woo v. Can J Diabetes. 2013 Apr;37(2):82-9. doi: 10.1016/j.jcjd.2013.02.055. Epub 2013 Apr 23. Can J Diabetes. 2013. PMID: 24070797
Pharmacologic management of type 2 diabetes.
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee; Harper W, Clement M, Goldenberg R, Hanna A, Main A, Retnakaran R, Sherifali D, Woo V, Yale JF. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, et al. Among authors: woo v. Can J Diabetes. 2013 Apr;37 Suppl 1:S61-8. doi: 10.1016/j.jcjd.2013.01.021. Epub 2013 Mar 26. Can J Diabetes. 2013. PMID: 24070965 No abstract available.
Hypoglycemia.
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee; Clayton D, Woo V, Yale JF. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, et al. Among authors: woo v. Can J Diabetes. 2013 Apr;37 Suppl 1:S69-71. doi: 10.1016/j.jcjd.2013.01.022. Epub 2013 Mar 26. Can J Diabetes. 2013. PMID: 24070966 No abstract available.
Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.
Gough SC, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, Damgaard LH, Buse JB; NN9068-3697 (DUAL-I) trial investigators. Gough SC, et al. Among authors: woo v. Lancet Diabetes Endocrinol. 2014 Nov;2(11):885-93. doi: 10.1016/S2213-8587(14)70174-3. Epub 2014 Sep 1. Lancet Diabetes Endocrinol. 2014. PMID: 25190523 Clinical Trial.
One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial.
Gough SC, Bode BW, Woo VC, Rodbard HW, Linjawi S, Zacho M, Reiter PD, Buse JB. Gough SC, et al. Among authors: woo vc. Diabetes Obes Metab. 2015 Oct;17(10):965-73. doi: 10.1111/dom.12498. Epub 2015 Jul 1. Diabetes Obes Metab. 2015. PMID: 25980900 Free PMC article. Clinical Trial.
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group. Green JB, et al. N Engl J Med. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8. N Engl J Med. 2015. PMID: 26052984 Free article. Clinical Trial.
Policies, Guidelines and Consensus Statements: Pharmacologic Management of Type 2 Diabetes-2015 Interim Update.
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee; Harper W, Clement M, Goldenberg R, Hanna A, Main A, Retnakaran R, Sherifali D, Woo V, Yale JF, Cheng AY; Steering Committee for Canadian Diabetes Association 2013 Clinical Practice Guidelines for Prevention and Management of Diabetes in Canada. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, et al. Among authors: woo v. Can J Diabetes. 2015 Aug;39(4):250-2. doi: 10.1016/j.jcjd.2015.05.009. Can J Diabetes. 2015. PMID: 26233723 Review. No abstract available.
REMOVED: Hypoglycemia.
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee; Clayton D, Woo V, Yale JF. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, et al. Among authors: woo v. Can J Diabetes. 2015 Nov;39 Suppl 4:6-8. doi: 10.1016/j.jcjd.2015.09.088. Can J Diabetes. 2015. PMID: 26541485 Retracted. No abstract available.
266 results